Vedolizumab Versus Adalimumab for Moderate to Severe Ulcerative Colitis
In the first clinical trial to evaluate two biologic therapies for moderate to severe ulcerative colitis (UC) head to head, Mount Sinai researchers found vedolizumab to be superior to adalimumab in a variety of measures.
Related People
The Dr. Burrill B. Crohn Professor of Medicine (Gastroenterology) and the Chief of the Division of Gastroenterology for the Mount Sinai Health System